Kazuhiko Nakagawa, MD, PhD, is a professor in the Department of Medical Oncology, Kindai University, Faculty of Medicine, in Japan, and he served as the lead principal investigator on the […] Read more
By Ben Solomon, MBBS, PhD, FRACP Posted: August 21, 2020 ROS1 rearrangements are found in 1% to 2% of patients with NSCLC. They tend to occur in never smokers and […] Read more
By Maria Antonia Velez, MD; Nanruoyi Zhou, BA; Brian Henick, MD; and Aaron Lisberg, MD Posted: August 21, 2020 Immune checkpoint inhibitors (CPIs) have revolutionized the treatment of metastatic NSCLC. […] Read more
By Kara Nyberg, PhD Posted: June 24, 2020 Given the variable response to immune checkpoint blockade, researchers have long sought to identify predictive biomarkers beyond PD-L1 to better select patients […] Read more
By Denis Moro-Sibilot, MD, MSc Posted: April 16, 2020 Dr. Denis Moro-Sibilot EGFR tyrosine kinase inhibitors (TKIs) are the standard of care for mutated EGFR NSCLC. Today, one of the […] Read more
This article is the second in a two-part series on ongoing challenges using immunotherapy in special populations. The first part of this series focused on patients with poor performance status. […] Read more
Letter to the Editor: Opening Trials to Patients Living with HIVBy Armelle Lavolé, AP-HP Hôpital Tenon, Paris, FrancePosted: August 14, 2019 In response to the article by Dr. Jarushka Naidoo, […] Read more
By Mirjana Rajer, MD, PhD Posted: April 1, 2019 For many years, the treatment of patients with stage III lung cancer has been a topic of intense debate among surgeons, radiation […] Read more
By Richard Booton, MD, PhD, FRCP Posted: April 1, 2019 Dr. Richard Booton The symptomatic presentation of lung cancer is typically associated with advanced disease and poor survival. Screening […] Read more
By Karen L. Reckamp, MD, MS Posted: March 1, 2019 Dr. Karen L. Reckamp Identification of genetic alterations in NSCLC has transformed diagnosis and treatment for patients with advanced disease. […] Read more